Research programme: Hedgehog cell-signalling pathway inhibitors - MAX BioPharma
Alternative Names: Hedgehog signalling pathway antagonists - MAX BioPharma; Liver X receptor agonists - MAX BioPharma; Oxysterol LXR agonists - MAX BioPharmaLatest Information Update: 28 Mar 2025
At a glance
- Originator MAX BioPharma
- Class Small molecules; Sterols
- Mechanism of Action Hedgehog cell signalling pathway inhibitors; Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma; Pancreatic cancer
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
- 28 Mar 2025 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 27 Mar 2023 Preclinical development for Pancreatic cancer and Multiple myeloma is ongoing in USA (MAX Biopharma website, March 2023)